New cell therapy company will treat solid tumours
Adaptimmune Therapeutics and TCR² Therapeutics’ new cell therapy company could…
Adaptimmune Therapeutics and TCR² Therapeutics’ new cell therapy company could gain the first approval for an engineered T-cell receptor (TCR) T-cell therapy for a solid tumour.